| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1378875 | Bioorganic & Medicinal Chemistry Letters | 2006 | 5 Pages |
Abstract
An imidazolylpyrimidine was identified in a CXCR2 chemokine receptor antagonist screen and was optimized for potency, in vitro metabolic stability, and oral bioavailability. It was found that subtle structural modification within the series affected the oral bioavailability. Potent and orally available CXCR2 antagonists are herein reported.
Graphical abstractImidazolylpyrimidine based CXCR2 chemokine receptor antagonist was optimized for potency, in vitro metabolic stability, and oral bioavailability. Potent and orally available CXCR2 antagonists are herein reported.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Koc-Kan Ho, Douglas S. Auld, Adolph C. Bohnstedt, Paolo Conti, Wim Dokter, Shawn Erickson, Daming Feng, Jim Inglese, Celia Kingsbury, Steven G. Kultgen, Rong-Qiang Liu, Christopher M. Masterson, Michael Ohlmeyer, Yajing Rong, Martijn Rooseboom,